Physician profile
Steven Smith
NPI 1750475836
$3,754.61
in general payments reported to CMS, 2019-2025
17 companies · $71.39 in 2025
The $71.39 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,734 · 2020: $140 · 2021: $356 · 2022: $270 · 2023: $183 · 2025: $71.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,382.00 | 2019 | |
| Stryker Corporation | $502.48 | 2019-2022 | |
| Depuy Synthes Sales INC. | $222.73 | 2019-2022 | |
| Horizon Therapeutics Plc | $167.40 | 2020-2022 | |
| Smith+Nephew, INC. | $152.94 | 2021-2023 | Real Intelligence |
| Titan Surgical Group, LLC | $71.39 | 2025 | |
| Baudax Bio INC. | $39.94 | 2021 | |
| Zimmer Biomet Holdings, INC. | $39.56 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $29.39 | 2021 | |
| Davol INC. | $26.33 | 2021 | |
| Heron Therapeutics, INC. | $23.82 | 2023 | Zynrelef |
| Acumed LLC | $19.45 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.72 | 2023 | Euflexxa |
| Pfizer INC. | $15.42 | 2020 | |
| Fx Shoulder Solutions, INC | $15.23 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $14.65 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.